| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1468-1331.2009.02568.X |
| P8608 | Fatcat ID | release_7z65vnm55zef3eowreyz4fbbte |
| P698 | PubMed publication ID | 19236457 |
| P50 | author | Søren H Sindrup | Q39378503 |
| Thomas Harbo | Q51811166 | ||
| P2093 | author name string | J Jakobsen | |
| H Andersen | |||
| K Hansen | |||
| A Hess | |||
| P2860 | cites work | Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. | Q53901414 |
| P433 | issue | 5 | |
| P921 | main subject | Multifocal motor neuropathy | Q6934690 |
| P304 | page(s) | 631-638 | |
| P577 | publication date | 2009-02-19 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial | |
| P478 | volume | 16 |
| Q56779123 | Q56779123 |
| Q48437188 | A comparison between intravenous and subcutmaneous immunogobulin |
| Q48644044 | A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study |
| Q37901520 | Bringing immunoglobulin knowledge up to date: how should we treat today? |
| Q38820288 | Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations |
| Q39217483 | Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®). |
| Q48301410 | Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan |
| Q24187946 | Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease |
| Q50205992 | Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin |
| Q34620111 | Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies |
| Q37550515 | Evidence-based treatment of chronic immune-mediated neuropathies |
| Q39604919 | High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. |
| Q92036804 | Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy |
| Q64048835 | Human immune globulin infusion in the management of multifocal motor neuropathy |
| Q38039965 | Immune pathogenesis and treatment of multifocal motor neuropathy |
| Q57476569 | Immune-mediated neuropathies |
| Q86421405 | Immunoglobulin (Ig) in multifocal motor neuropathy (MMN): update on evidence for Ig treatment in MMN |
| Q37729945 | Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home |
| Q36484418 | Immunotherapy in Peripheral Neuropathies |
| Q37836898 | Immunotherapy of multifocal motor neuropathy |
| Q51649208 | Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. |
| Q37877259 | Indications and safety of intravenous and subcutaneous immunoglobulin therapy |
| Q33420267 | Intravenous immunoglobulin as clinical immune-modulating therapy |
| Q38228519 | Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review |
| Q47584292 | Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q28390264 | Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants |
| Q37696931 | Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment |
| Q38091664 | Multifocal motor neuropathy: current therapies and novel strategies. |
| Q37959252 | Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies |
| Q42775420 | New Frontiers in Subcutaneous Immunoglobulin Treatment |
| Q38270717 | Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach |
| Q40793045 | Outcome measures in MMN revisited: further improvement needed |
| Q47585442 | Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy |
| Q26864907 | Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies |
| Q38171572 | Subcutaneous IgG in neurologic diseases |
| Q36094658 | Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study |
| Q37125900 | Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial |
| Q51134410 | Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy. |
| Q44954147 | Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study |
| Q35780802 | Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders |
| Q37890936 | Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. |
| Q38152428 | Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects |
| Q84468963 | Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report |
| Q37626132 | Subcutaneous immunoglobulin: opportunities and outlook |
| Q26745685 | Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies |
| Q39370917 | Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis. |
| Q34457953 | Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q35537340 | The pathogenesis of multifocal motor neuropathy and an update on current management options |
| Q87044605 | Treatment of multifocal motor neuropathy |
| Q48387989 | Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry |
| Q36737563 | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| Q45640650 | Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders |
| Q84475530 | [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010] |
Search more.